Editas Medicine Inc [EDIT] stock is trading at $4.08, up 3.03%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EDIT shares have gain 9.09% over the last week, with a monthly amount drifted -27.27%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on August 08, 2024, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $15 from $13. Previously, Morgan Stanley upgraded its rating to Equal-Weight on May 09, 2024, and kept the price target unchanged to $7. On October 24, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $11 on the stock. JP Morgan upgraded its rating to a Neutral but stick to its price target of $8 on October 18, 2023. Cantor Fitzgerald downgraded its rating to a Neutral. Stifel upgraded its rating to Buy for this stock on September 29, 2023, and upped its price target to $17. In a note dated June 12, 2023, Raymond James upgraded an Outperform rating on this stock but restated the target price of $17.
Editas Medicine Inc [EDIT] stock has fluctuated between $3.71 and $11.69 over the past year. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $4.08 at the most recent close of the market. An investor can expect a potential return of 316.67% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
Editas Medicine Inc [NASDAQ:EDIT] reported sales of 67.03M for the trailing twelve months, which represents a drop of -82.23%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -3.1%, Pretax Profit Margin comes in at -2.89%, and Net Profit Margin reading is -2.89%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.63 and Total Capital is -0.67. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.97 points at the first support level, and at 3.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.17, and for the 2nd resistance point, it is at 4.26.
Ratios To Look Out For
For context, Editas Medicine Inc’s Current Ratio is 3.85. Further, the Quick Ratio stands at 3.85, while the Cash Ratio is 0.87. Considering the valuation of this stock, the price to sales ratio is 5.02, the price to book ratio is 1.45.
Transactions by insiders
Recent insider trading involved Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER, that happened on Jul 25 ’24 when 11886.0 shares were sold. EVP, CHIEF MEDICAL OFFICER, Mei Baisong completed a deal on Jul 19 ’24 to sell 6619.0 shares. Meanwhile, CEO O’Neill Gilmore Neil sold 12191.0 shares on Jun 04 ’24.
